Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Jan 31;13(1):205-209.
doi: 10.21037/tlcr-23-578. Epub 2024 Jan 11.

Will perioperative pembrolizumab treatment change perioperative treatment strategies for resectable non-small cell lung cancer?

Shuji Murakami  1
Affiliations
Editorial

Will perioperative pembrolizumab treatment change perioperative treatment strategies for resectable non-small cell lung cancer?

Shuji Murakami. Transl Lung Cancer Res. .
No abstract available

Keywords: Early-stage non-small cell lung cancer (early-stage NSCLC); pembrolizumab; perioperative immune checkpoint inhibitor (perioperative ICI).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-578/coif). S.M. received grants from AstraZeneca, Takeda, Chugai Pharmaceuticals, Sanofi, MSD, Daiichi Sanky, Ono Pharmaceuticals, and Janssen Pharma, as well as lecture fees from AstraZeneca, Chugai Pharmaceuticals, Takeda, Eli Lilly, MSD, Pfizer, Novartis, and Taiho Pharmaceuticals. The author has no other conflicts of interest to declare.

Comment on

  • Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.

References

    1. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med 2020;383:640-9. 10.1056/NEJMoa1916623 - DOI - PMC - PubMed
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Scagliotti GV, Pastorino U, Vansteenkiste JF, et al. Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol 2012;30:172-8. 10.1200/JCO.2010.33.7089 - DOI - PubMed
    1. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet 2014;383:1561-71. 10.1016/S0140-6736(13)62159-5 - DOI - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. 10.1056/NEJMoa1606774 - DOI - PubMed